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Introduction {#asj12619-sec-0001}
============

Broiler chickens, which are bred for rapid growth and high meat yield, do not adequately control voluntary food intake to meet their energy requirements (Richards & Proszkowiec‐Weglarz [2007](#asj12619-bib-0064){ref-type="ref"}). Consequently, their overconsumption of food can lead to excessive accumulation of visceral fat, which is regarded as an animal by‐product or as waste. Furthermore, data on energy from fat and protein in chicken (1870‐2004) reveal that while chicken was at one time a lean, low‐fat food, this is no longer true (Wang *et al*. [2010](#asj12619-bib-0084){ref-type="ref"}). Thus, the regulatory mechanisms underlying food intake in chickens have been a focus of research in recent decades to improve production efficiency when raising chickens (Kuenzel [1994](#asj12619-bib-0043){ref-type="ref"}; Furuse [2002](#asj12619-bib-0019){ref-type="ref"}; Richards & Proszkowiec‐Weglarz [2007](#asj12619-bib-0064){ref-type="ref"}; Bungo *et al*. [2011](#asj12619-bib-0010){ref-type="ref"}).

In mammals, a single *glucagon* gene encodes three distinct structurally related peptides: oxyntomodulin (OXM), glucagon‐like peptide (GLP)‐1 and GLP‐2 are produced in the intestine and brain, whereas glucagon is produced from the same precursor in the pancreas (Janssen *et al*. [2013](#asj12619-bib-0040){ref-type="ref"}). In contrast, nonmammalian vertebrates utilize more complex mechanisms for the production of proglucagon‐derived peptides. For example, chickens have a single proglucagon gene that expresses multiple messenger RNA (mRNA) transcripts (Fig. [1](#asj12619-fig-0001){ref-type="fig"}) (Richards & McMurtry [2009](#asj12619-bib-0063){ref-type="ref"}). Fish and amphibians have either multiple proglucagon genes or exons that are likely the result of duplication events (Ng *et al*. [2010](#asj12619-bib-0057){ref-type="ref"}). Recently, a novel GLP (GCGL) and its receptor (GCGLR) have been identified in chickens as well as in other nonmammalian vertebrates (Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}). To date, *GCGL* and its receptor genes have not been identified in any mammalian species, implying that they might have been lost during evolution. Figure [2](#asj12619-fig-0002){ref-type="fig"} shows the alignment of glucagon‐related peptides from different species. The amino acid sequence of glucagon was highly conserved between mammals and chickens, whereas that of GLP‐2 was not. These findings raise the hypothesis that glucagon‐related peptides play different physiological roles among vertebrates. This review provides current knowledge about the possible roles of glucagon‐related peptides in the appetite regulatory systems in chickens.

![Chicken glucagon, oxyntomodulin (OXM), glucagon‐like peptide (GLP)‐1 and GLP‐2 are produced in a tissue‐specific manner. Two messenger RNA (RNA) classes, PGA (pancreas) and PGB (brain and gut), are produced by alternate promoter and alternate first exon usage. Translation of these mRNAs produces preproglucagon A or preproglucagon B. In the pancreas, proglucagon A is cleaved by PC1/3 to generate glucagon. In the brain and gut, the proglucagon B is cleaved by PC2 to generate glicentin, OXM, GLP‐1 and GLP‐2.](ASJ-87-1090-g001){#asj12619-fig-0001}

![Alignment of glucagon‐related peptides from different species. Dashes indicate amino acids identical to chicken peptides. Amino acid sequences of glucagon‐related peptides were retrieved from articles (Ng *et al*. [2010](#asj12619-bib-0057){ref-type="ref"}; Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}; Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}).](ASJ-87-1090-g002){#asj12619-fig-0002}

Glucagon {#asj12619-sec-0002}
--------

The anorexigenic effect of glucagon was first reported in mammals: intracerebroventricular (ICV) administration of glucagon in rats significantly decreased food intake (Inokuchi *et al*. [1984](#asj12619-bib-0037){ref-type="ref"}). The anorexigenic effect of ICV administration of glucagon was also found in chicks (Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}) and sheep (Kurose *et al*. [2009](#asj12619-bib-0044){ref-type="ref"}). Although the mechanisms underlying the anorexigenic action of glucagon in mammals and birds are not fully understood, the possible mechanisms are similar in some respects.

ICV administration of glucagon induced hyperglycemia in chicks (Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}, [2012](#asj12619-bib-0029){ref-type="ref"}, [2015a](#asj12619-bib-0030){ref-type="ref"}). Intravascular administration of glucose significantly decreased food intake in chicks (Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}). It is therefore likely that hyperglycemia‐mediated pathways are also involved in the anorexigenic action of glucagon in chicks. Central glucagon‐induced hyperglycemia was observed in rats (Marubashi *et al*. [1985](#asj12619-bib-0048){ref-type="ref"}), mice (Amir [1986](#asj12619-bib-0003){ref-type="ref"}), dogs (Agarwala *et al*. [1986](#asj12619-bib-0002){ref-type="ref"}) and sheep (Kurose *et al*. [2009](#asj12619-bib-0044){ref-type="ref"}). Phentolamine, an α‐adrenergic receptor antagonist, significantly attenuated glucagon‐induced hyperglycemia in rats (Marubashi *et al*. [1985](#asj12619-bib-0048){ref-type="ref"}) and chicks (Honda *et al*. [2012](#asj12619-bib-0029){ref-type="ref"}). These findings suggest that glucagon induces hyperglycemia at least partly via the α‐adrenergic neural pathway both in mammals and chicks.

ICV administration of glucagon dramatically increased plasma corticosterone concentration in chicks, suggesting the activation of the hypothalamic pituitary adrenal (HPA) axis (Honda *et al*. [2012](#asj12619-bib-0029){ref-type="ref"}). Corticotropin‐releasing factor (CRF), the upstream regulator of HPA axis, was also suggested to be a mediator for a number of anorexigenic peptides in chickens (Meade & Denbow [2003](#asj12619-bib-0049){ref-type="ref"}; Tachibana *et al*. [2004](#asj12619-bib-0075){ref-type="ref"}, [2006](#asj12619-bib-0076){ref-type="ref"}; Honda *et al*. [2007b](#asj12619-bib-0028){ref-type="ref"}; Kamisoyama *et al*. [2007](#asj12619-bib-0041){ref-type="ref"}). ICV administration of glucagon significantly increased the hypothalamic CRF mRNA level in chicks (Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}). These findings suggest that CRF acts as a downstream molecule for a glucagon‐induced appetite‐suppressive pathway in chicks.

Electrophoretic application of glucagon to hypothalamic neurons in rats suppressed the neuronal activity of glucose‐sensitive neurons in the lateral hypothalamic area (LHA) but not in the ventromedial hypothalamic nucleus (VMH) and dorsomedial hypothalamic nucleus (DMH) (Inokuchi *et al*. [1986](#asj12619-bib-0038){ref-type="ref"}). Glucagon administration into the paraventricular nucleus in rats did not influence food intake (Atrens & Menendez [1993](#asj12619-bib-0004){ref-type="ref"}). These findings suggest that LMH is the target site of glucagon to exert its anorexogenic effect in mammals. In birds, the greatest expression of glucagon receptor was consistently detected in the hypothalamus of chickens (Wang *et al*. [2008](#asj12619-bib-0086){ref-type="ref"}). Montaron *et al*. ([1994](#asj12619-bib-0055){ref-type="ref"}) used radioautography to detect and localize glucagon receptors in the duck brain. Further study will be needed to identify the target site of glucagon in the chicken hypothalamus.

There is evidence that glucagon can be transported from blood into the cerebrospinal fluid in humans (Graner & Abraira [1985](#asj12619-bib-0026){ref-type="ref"}). It is therefore possible that peripheral glucagon can access the target site of the brain in chicks. However, plasma glucagon level is elevated under fasting condition in chickens (Dupont *et al*. [2008](#asj12619-bib-0017){ref-type="ref"}; Richards & McMurtry [2008](#asj12619-bib-0062){ref-type="ref"}). Therefore, it is not reasonable to assume that glucagon suppresses appetite under conditions of hunger. One possible explanation is proposed by Filippi *et al*. ([2013](#asj12619-bib-0018){ref-type="ref"}): elevations in circulating glucagon levels that elevate brain glucagon levels may occur during conditions of stress, during which suppression of the desire to eat may be beneficial to divert the body\'s attention to a 'fight‐or‐flight' response. Further study will be needed to clarify this possibility in chickens.

Oxyntomodulin {#asj12619-sec-0003}
-------------

OXM is released from the intestines into the blood in response to food ingestion and in proportion to energy intake (Ghatei *et al*. [1983](#asj12619-bib-0024){ref-type="ref"}; Le Quellec *et al*. [1992](#asj12619-bib-0046){ref-type="ref"}). Central or peripheral administration of OXM suppressed food intake in mammals (Dakin *et al*. [2001](#asj12619-bib-0013){ref-type="ref"}; Cohen *et al*. [2003](#asj12619-bib-0012){ref-type="ref"}), suggesting that OXM plays a physiological role as a satiety signal and anorexigenic neuropeptide in mammals. In chickens, the anorexigenic effect of OXM was reported by two different groups: ICV administration of bovine OXM significantly suppressed food intake (Cline *et al*. [2008](#asj12619-bib-0011){ref-type="ref"}; Moghaddam *et al*. [2010](#asj12619-bib-0051){ref-type="ref"}). However, as shown in Figure [2](#asj12619-fig-0002){ref-type="fig"}, the amino acid sequence of bovine OXM differs from that of chicken OXM: chicken OXM contains the 29 amino acid sequence of chicken glucagon followed by a 26 amino acid C‐terminal extension, whereas bovine OXM contains the 29 amino acid sequence of bovine glucagon followed by a shorter sequence of eight residues at its C‐terminal. Mammalian peptide, which has a similar but not identical amino acid sequence to chicken peptide, showed different effects on food intake when centrally administered (Shiraishi *et al*. [2009](#asj12619-bib-0070){ref-type="ref"}; [Saneyasu *et al*. 2011a](#asj12619-bib-0066){ref-type="ref"}). In fact, ICV administration of chicken OXM significantly suppressed food intake in broiler and layer chicks (Honda *et al*. [2014a](#asj12619-bib-0032){ref-type="ref"}). It is therefore possible that OXM functions as an anorexigenic peptide in chicks.

Chicken OXM significantly increased plasma glucose and corticosterone levels (Honda *et al*. [2014a](#asj12619-bib-0032){ref-type="ref"}). Similar changes in plasma glucose and corticosterone are induced by glucagon (Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}, [2012](#asj12619-bib-0029){ref-type="ref"}) but not by GLP‐1 (Honda *et al*. [2014a](#asj12619-bib-0032){ref-type="ref"}) or GLP‐2 (Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}) when centrally administered. OXM receptor gene or its mRNA was not identified in the chicken genome or chicken expressed sequence tag (EST) databases. Therefore, it seems likely that OXM suppresses food intake via glucagon receptor in chicks.

OXM contains the 29 amino acid glucagon sequence in the N‐terminal region. Prévost *et al*. ([2012](#asj12619-bib-0061){ref-type="ref"}) reported that F22, V23, M27 and D15 of glucagon are the most important residues for receptor binding. These four amino acid residues are conserved in chicken and bovine OXM. In addition, both glucagon and OXM induced anorexia and hyperglycemia in chicks (Honda *et al*. [2012](#asj12619-bib-0029){ref-type="ref"}, [2014a](#asj12619-bib-0032){ref-type="ref"}). These findings suggest that the N‐terminal glucagon region plays an important role in the anorexigenic action of OXM. However, in mammals, growing evidence suggests that OXM suppresses food intake via GLP‐1 receptor. For example, the anorexigenic effect of OXM was blocked by co‐administration of the GLP‐1 receptor antagonist exendin in rats (Dakin *et al*. [2001](#asj12619-bib-0013){ref-type="ref"}). The anorexigenic effect of OXM is preserved in glucagon receptor null mice but abolished in GLP‐1 receptor null mice (Baggio *et al*. [2004](#asj12619-bib-0005){ref-type="ref"}). It is therefore likely that OXM‐induced anorexigenic pathways are different between mammals and chicks.

Dakin *et al*. ([2004](#asj12619-bib-0014){ref-type="ref"}) reported that OXM increases c‐FOS in the arcuate nucleus of rats. In chickens, c‐FOS immunoreactivity was significantly decreased in the Leghorn male hepatoma and significantly increased in the nucleus infundibuli hypothalami (equivalent of the mammalian arcuate nucleus) by ICV administration of OXM (Cline *et al*. [2008](#asj12619-bib-0011){ref-type="ref"}). Therefore, the OXM induced anorexigenic pathway in the brain might be partly conserved between mammals and chickens.

Glucagon‐like peptide‐1 {#asj12619-sec-0004}
-----------------------

In 1996, Turton *et al*. ([1996](#asj12619-bib-0081){ref-type="ref"}) first reported that ICV administration of GLP‐1 suppresses food intake in mammals. The GLP‐1‐producing neuron in the nucleus tractus solitarii (NTS) of the brainstem is an important site within the regulatory pathways of feeding in mammals (Van Bloemendaal *et al*. [2014](#asj12619-bib-0082){ref-type="ref"}). Thus, GLP‐1 is considered as an anorexigenic neurotransmitter in mammals. In chickens, ICV administration of chicken GLP‐1 significantly suppressed food intake (Furuse *et al*. [1997a](#asj12619-bib-0022){ref-type="ref"}). GLP‐1‐immunoreactive perikarya were found in the NTS (Tachibana *et al*. [2005](#asj12619-bib-0073){ref-type="ref"}). Proglucagon mRNA level in the brainstem or medulla oblongata was decreased after 24 h fasting in chicks (Tachibana *et al*. [2005](#asj12619-bib-0073){ref-type="ref"}; Honda *et al*. [2015c](#asj12619-bib-0034){ref-type="ref"}). Chicken GLP1R was highly expressed in the telencephalon, midbrain, hindbrain and hypothalamus (Huang *et al*. [2012](#asj12619-bib-0036){ref-type="ref"}). All these findings suggest that GLP‐1 functions as an anorexigenic peptide in the central nervous system in chicks.

GLP‐1 is released from the intestine in response to food ingestion in mammals (Tolhurst *et al*. [2009](#asj12619-bib-0080){ref-type="ref"}). Meta‐analysis revealed that intravascular administration of GLP‐1 dose‐dependently reduces energy intake in humans (Verdich *et al*. [2001](#asj12619-bib-0083){ref-type="ref"}). Thus, GLP‐1 is also considered as a peripheral satiety hormone in mammals (Van Bloemendaal *et al*. [2014](#asj12619-bib-0082){ref-type="ref"}). In birds, intraperitoneal administration of 3 nmol/kg body weight GLP‐1 did not affect food intake in layer chicks under 15 h fasting (Tachibana *et al*. [2003](#asj12619-bib-0074){ref-type="ref"}). On the other hand, intraperitoneal administration of 0.5 nmol/body rat GLP‐1 significantly suppressed food intake in Japanese quails (Shousha *et al*. [2007](#asj12619-bib-0071){ref-type="ref"}). In addition, intravascular administration of 1.5 nmol/kg body weight GLP‐1 in broiler chicks significantly suppressed food intake under *ad libitum* feeding conditions (Honda K, unpublished data). Recent findings in immunohistochemical and morphometric studies of chickens suggested that GLP‐1 plays physiological roles as one of the common hormones secreted by L cells in the chicken small intestine (Nishimura *et al*. [2013](#asj12619-bib-0058){ref-type="ref"}; [2014a](#asj12619-bib-0052){ref-type="ref"}, [2014b](#asj12619-bib-0054){ref-type="ref"}). For example, frequencies of occurrence of GLP‐1‐immunoreactive cells were influenced by food deprivation in chickens (Monir *et al*. [2014a](#asj12619-bib-0052){ref-type="ref"}) and dietary protein levels ([Monir *et al*. 2014b](#asj12619-bib-0054){ref-type="ref"}). It is therefore likely that GLP‐1 functions as an anorexigenic peptide not only in the central nervous system but also in the peripheral circulation in chickens.

Turton *et al*. ([1996](#asj12619-bib-0081){ref-type="ref"}) reported that deletion of N‐terminal histidine of GLP‐1 eliminated the anorexigenic effect in rats, suggesting that the N‐terminal histidine has an important role in the anorexigenic action of GLP‐1. In chickens, the anorexigenic effects of modified mammalian GLP‐1 in which N‐terminal histidine was substituted for tyrosine was 11‐ to 13‐fold less than that of non‐modified GLP‐1 ([Bungo *et al*. 1999a](#asj12619-bib-0009){ref-type="ref"}). Furuse *et al*. ([1998a](#asj12619-bib-0020){ref-type="ref"}) reported that the threshold of full‐length mammalian GLP‐1‐induced anorexia was lower than that of C‐terminal‐truncated GLP‐1 in chicks. These findings suggest that both the N‐ and C‐terminal regions of GLP‐1 may have important roles for the regulation of food intake in chickens.

ICV administration of the GLP‐1 receptor antagonist exendin, enhanced food intake in rats (Turton *et al*. [1996](#asj12619-bib-0081){ref-type="ref"}) and layer chicks (Furuse *et al*. [1998b](#asj12619-bib-0021){ref-type="ref"}; Tachibana *et al*. [2001](#asj12619-bib-0077){ref-type="ref"}) but not in broiler chicks (Tachibana *et al*. [2001](#asj12619-bib-0077){ref-type="ref"}). Broiler chicks eat more food than layer chicks ([Saneyasu *et al*. 2011b](#asj12619-bib-0065){ref-type="ref"}). It is therefore possible that the expression of endogenous GLP‐1 in broiler chicks is lower than that in layer chicks, which in turn results in hyperphagia in boiler chicks. However, exendin also attenuates GLP‐2‐induced anorexia in chicks (Honda K, unpublished data), suggesting that exendin acts as a dual antagonist of GLP‐1 receptor and GLP‐2 receptor in chickens. Further study will be needed to investigate the ligand specificity of chicken glucagon‐related receptors in more detail using commonly used antagonists and agonists for mammalian glucagon‐related receptors.

CRF is suggested to be a downstream mediator of the GLP‐1‐induced anorexigenic pathway in rats (Larsen *et al*. [1997](#asj12619-bib-0045){ref-type="ref"}; Sarkar *et al*. [2003](#asj12619-bib-0067){ref-type="ref"}; Gotoh *et al*. [2005](#asj12619-bib-0025){ref-type="ref"}). In layer chicks, ICV administration of GLP‐1 significantly increased plasma corticosterone concentration, suggesting that GLP‐1 activates the HPA axis (Tachibana *et al*. [2006](#asj12619-bib-0076){ref-type="ref"}). Furthermore, the anorexigenic effect of GLP‐1 was attenuated by the co‐administration of the CRF antagonist, astressin, in layer chicks (Tachibana *et al*. [2006](#asj12619-bib-0076){ref-type="ref"}). In contrast, ICV administration of GLP‐1 did not alter plasma corticosterone concentration in broiler chicks (Furuse *et al*. [1997b](#asj12619-bib-0023){ref-type="ref"}). These findings suggest that CRF is involved in the inhibitory mechanisms of GLP‐1 for feeding, at least in layer chicks as well as in mammals.

GLP‐1 ([Bungo *et al*. 1999b](#asj12619-bib-0008){ref-type="ref"}) and noradrenalin (Denbow *et al*. [1981](#asj12619-bib-0015){ref-type="ref"}) induced sedation in chicks when centrally administered. In addition, ICV administration of fusaric acid, an inhibitor of noradrenaline synthesis, attenuated the suppression of food intake by GLP‐1 in a dose‐related fashion (Bungo *et al*. [2001](#asj12619-bib-0007){ref-type="ref"}). ICV administration of GLP‐1 in chicks decreased monoamine concentrations and stimulated the expression of FOS‐like immunoreactive cells in the ventromedial nuclei (Tachibana *et al*. [2002](#asj12619-bib-0078){ref-type="ref"}). These findings suggest that the noradrenergic system in the brain is involved in the GLP‐1‐induced anorexigenic pathway in chicks.

Glucagon‐like peptide‐2 {#asj12619-sec-0005}
-----------------------

GLP‐2 is produced in the brain and gut as described above. ICV administration of GLP‐2 suppressed food intake and increased c‐FOS immunoreactive nuclei in the DMN in rat brain (Tang‐Christensen *et al*. [2000](#asj12619-bib-0079){ref-type="ref"}). There is evidence that GLP‐2 receptor was expressed in the appetite regulation‐related brain regions, such as DMH, VMH and NTS in rats (Tang‐Christensen *et al*. [2000](#asj12619-bib-0079){ref-type="ref"}; Lovshin *et al*. [2004](#asj12619-bib-0047){ref-type="ref"}). Thus, GLP‐2 is considered as an anorexigenic neurotransmitter in mammals. In birds, Shousha *et al*. ([2007](#asj12619-bib-0071){ref-type="ref"}) first reported that ICV administration of rat GLP‐2 did not influence food intake in Japanese quails. However, mammalian GLP‐2 shares only 51‐55% amino acid identity with chicken GLP‐2 (Fig. [1](#asj12619-fig-0001){ref-type="fig"}). There is evidence that GLP‐2 receptor was expressed in the brain of chickens (Richards & McMurtry [2008](#asj12619-bib-0062){ref-type="ref"}; Mo *et al*. [2014](#asj12619-bib-0050){ref-type="ref"}). In fact, ICV administration of chicken GLP‐2, but not human GLP‐2, potently suppressed food intake (Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}). Also, ICV administration of chicken GLP‐2 significantly decreased plasma glucose concentration and did not affect plasma corticosterone concentration, suggesting that the mechanism underlying the anorexigenic action of GLP‐2 differs from that of glucagon and OXM in chicks (Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}). Furthermore, ICV administration of an equimolar amount of GLP‐1 and GLP‐2, but not OXM, significantly suppressed food intake in chicks (Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}). These findings suggest that GLP‐2 may function as a powerful anorexigenic peptide in the central nervous system in chicks.

Peripheral GLP‐2 is known to be an intestinotrophic peptide (Drucker *et al*. [1996](#asj12619-bib-0016){ref-type="ref"}). Studies in humans have not demonstrated a satiety effect of peripheral GLP‐2 (Schmidt *et al*. [2003](#asj12619-bib-0068){ref-type="ref"}; Sorensen *et al*. [2003](#asj12619-bib-0072){ref-type="ref"}). However, recent data have shown that intraperitoneal injection of GLP‐2 reduces food intake in lean and obese mice, suggesting a role of GLP‐2 in the short‐term regulation of food intake (Baldassano *et al*. [2012](#asj12619-bib-0006){ref-type="ref"}). Also, intravascular administration of chicken GLP‐2 significantly suppressed food intake in chicks (Honda *et al*. [2015c](#asj12619-bib-0034){ref-type="ref"}), although peripheral administration of mammalian GLP‐2 did not influence food intake in chickens and Japanese quails (Shousha *et al*. [2007](#asj12619-bib-0071){ref-type="ref"}; Hu *et al*. [2010](#asj12619-bib-0035){ref-type="ref"}). Immunohistochemical and morphometric studies of chickens suggested that GLP‐2 colocalized with GLP‐1 in the same secretory granules of L cells in the chicken small intestine (Nishimura *et al*. [2013](#asj12619-bib-0058){ref-type="ref"}; [Monir *et al*. 2014c](#asj12619-bib-0053){ref-type="ref"}). These findings suggest that GLP‐2 may act as a postprandial satiety hormone in chickens.

Novel glucagon‐like peptide {#asj12619-sec-0006}
---------------------------

Recently, GCGL and its receptor GCGLR were identified in the chicken brain (Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}). Genomic analysis revealed that the *GCGL* gene is located in a synteny conserved in tilapia, coelacanth, *Xenopus*, and chickens, but not in humans (Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}). GCGL and GCGLR were detected in chicken and *Xenopus tropicalis* brains by RT‐PCR (Irwin & Prentice [2011](#asj12619-bib-0039){ref-type="ref"}; Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}), implying that GCGL and its receptor may play important roles in the central nervous system of nonmammalian vertebrates.

A comparatively high mRNA expression level of GCGL was detected in the hypothalamus of chickens (Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}). The hypothalamus plays a critical role in appetite regulation in mammals (Schneeberger *et al*. [2014](#asj12619-bib-0069){ref-type="ref"}) and birds (Richards & Proszkowiec‐Weglarz [2007](#asj12619-bib-0064){ref-type="ref"}; Bungo *et al*. [2011](#asj12619-bib-0010){ref-type="ref"}). In fact, ICV administration of GCGL significantly suppressed food intake in both layer and broiler chicks (Honda *et al*. [2014b](#asj12619-bib-0033){ref-type="ref"}). The anorexigenic effect of GCGL was attenuated by the co‐administration of the CRF antagonist, α‐helical CRF, in chicks (Honda *et al*. [2014b](#asj12619-bib-0033){ref-type="ref"}). Twenty‐four hours of fasting did not affect hypothalamic mRNA levels of GCGL and GCGLR in chicks, suggesting that endogenous GCGL does not change in response to nutritional status in chicks. However, it is possible that GCGL functions as an anorexigenic peptide in the brain in chicks. Further study will be needed to determine the changes of physiological concentration of neuronal GCGL in chicks.

Ligand specificiity of receptors of glucagon‐related peptides {#asj12619-sec-0007}
-------------------------------------------------------------

Lines of evidence suggest that glucagon, GLP‐1, GLP‐2 and GCGL specifically activate their receptors in chickens. For example, chicken glucagon receptor was activated by glucagon but not by GLP‐1 and GLP‐2 *in vitro* (Wang *et al*. [2012](#asj12619-bib-0085){ref-type="ref"}). Chicken GLP‐1 receptor expressed in Chinese hamster ovary cells was potently activated by GLP‐1 but not by glucagon and GLP‐2 (Huang *et al*. [2012](#asj12619-bib-0036){ref-type="ref"}). Recently, Mo *et al*. ([2014](#asj12619-bib-0050){ref-type="ref"}) demonstrated that chicken GLP‐2 receptor expressed in Chinese hamster ovary cells was potently activated by chicken GLP‐2 but not by other structurally related peptides, including chicken GLP‐1 and glucagon. Wang *et al*. ([2012](#asj12619-bib-0085){ref-type="ref"}) reported that GCGL was 300‐fold more potent in activating GCGLR than any other peptide, including glucagon, GLP‐1 and GLP‐2, suggesting that GCGLR is a receptor specific to GCGL.

To date, a distinct receptor for OXM has not yet been identified. Therefore, OXM seems to be a dual agonist of GLP‐1 receptor and the glucagon receptor in mammals (Pocai [2012](#asj12619-bib-0060){ref-type="ref"}). However, recent findings suggest that OXM suppresses food intake via glucagon receptor in chicks (Honda *et al*. [2014b](#asj12619-bib-0033){ref-type="ref"}), as described earlier. Therefore, it is possible that the physiological roles of OXM are different between mammals and chickens.

Routes of the anorexigenic actions of peripheral GLP‐1 and GLP‐2 {#asj12619-sec-0008}
----------------------------------------------------------------

In mammals, GLP‐1 can directly stimulate anorectic pathways in the hypothalamus and brainstem, and may also act through the vagus nerve (Murphy & Bloom [2006](#asj12619-bib-0056){ref-type="ref"}; Van Bloemendaal *et al*. [2014](#asj12619-bib-0082){ref-type="ref"}). For example, GLP‐1 receptors in the subfornical organ and the area postrema are accessible to circulating GLP‐1 (Orskov *et al*. [1996](#asj12619-bib-0059){ref-type="ref"}). A radiolabelled GLP‐1 analogue has been demonstrated to easily cross the blood‐brain barrier in mice (Kastin *et al*. [2002](#asj12619-bib-0042){ref-type="ref"}). Vagotomy has been reported to block or attenuate the anorexgenic effect of GLP‐1 in rats (Abbott *et al*. [2005](#asj12619-bib-0001){ref-type="ref"}). In chickens, GLP‐1 receptor and GLP‐2 receptor mRNAs are widely distributed in the gastrointestinal tract (Huang *et al*. [2012](#asj12619-bib-0036){ref-type="ref"}; Mo *et al*. [2014](#asj12619-bib-0050){ref-type="ref"}). Therefore, it is possible that both GLP‐1 and GLP‐2 signals are received by the brainstem as neural inputs through the vagal afferent nerves from the gastrointestinal tract in chickens. Further studies in chickens will be needed to clarify: (i) whether circulating GLPs can directly access these receptors in the brain; (ii) whether the vagal afferent nerves are related to the anorexigenic effect of GLPs; and (iii) whether circulating GLPs postprandially elevate.

Conclusion {#asj12619-sec-0009}
----------

Recent evidence suggests that glucagon‐related peptides show anorexigenic action in chicks. Lines of evidence suggest that the physiological roles of these peptides in chickens differ from those of mammals. In addition, the anorexigenic effects of GLP‐1 and GLP‐2 were expressed at a very low dose when compared to other glucagon‐related peptides in chicks (Table [1](#asj12619-tbl-0001){ref-type="table-wrap"}), suggesting that GLP‐1 and GLP‐2 may play an important role in the regulation of food intake in chicks. Further studies will be needed to evaluate the physiological importance of glucagon‐related peptides in the regulation of food intake in chickens.

###### 

The minimal effective doses of chicken glucagon‐related peptides that suppress food intake for 2 h after intracerebroventricular administration in 8‐day‐old layer chicks

  Peptide                       Minimal effective dose   Reference
  ----------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------
  Glucagon                      300 pmol                 Honda *et al*. [2007a](#asj12619-bib-0027){ref-type="ref"}
  Glucagon‐like peptide‐1       30 pmol                  Honda *et al*. [2014a](#asj12619-bib-0032){ref-type="ref"}, [2015b](#asj12619-bib-0031){ref-type="ref"}
  Glucagon‐like peptide‐2       30 pmol                  Honda *et al*. [2015b](#asj12619-bib-0031){ref-type="ref"}
  Oxyntomodulin                 300 pmol                 Honda *et al*. [2014a](#asj12619-bib-0032){ref-type="ref"}
  Novel glucagon‐like pepitde   1000 pmol                Honda *et al*. [2014b](#asj12619-bib-0033){ref-type="ref"}
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